These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 15375314)
41. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy. Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938 [TBL] [Abstract][Full Text] [Related]
42. Clinical development of antisense oligonucleotides as anti-cancer therapeutics. Chen HX Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768 [No Abstract] [Full Text] [Related]
43. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666 [TBL] [Abstract][Full Text] [Related]
44. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680 [TBL] [Abstract][Full Text] [Related]
45. Antisense oligonucleotides: from design to therapeutic application. Chan JH; Lim S; Wong WS Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890 [TBL] [Abstract][Full Text] [Related]
46. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837 [TBL] [Abstract][Full Text] [Related]
47. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance. Funato T Methods Mol Med; 2005; 106():215-33. PubMed ID: 15375319 [No Abstract] [Full Text] [Related]
48. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy. Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046 [TBL] [Abstract][Full Text] [Related]
49. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry SP; Monteith D; Bennett F; Levin AA Anticancer Drug Des; 1997 Jul; 12(5):409-20. PubMed ID: 9236856 [No Abstract] [Full Text] [Related]
50. Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. Sonnemann J; Gekeler V; Ahlbrecht K; Brischwein K; Liu C; Bader P; Müller C; Niethammer D; Beck JF Cancer Lett; 2004 Jun; 209(2):177-85. PubMed ID: 15159020 [TBL] [Abstract][Full Text] [Related]
52. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. Baba M; Iishi H; Tatsuta M Int J Cancer; 2000 Jan; 85(2):260-6. PubMed ID: 10629087 [TBL] [Abstract][Full Text] [Related]
53. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice. Kobzdej M; Matuszyk J; Strzadala L Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643 [TBL] [Abstract][Full Text] [Related]
54. Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both? Loriot Y; Mordant P; Deutsch E Ann Oncol; 2009 Mar; 20(3):596-7; author reply 597. PubMed ID: 19164457 [No Abstract] [Full Text] [Related]
55. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461 [TBL] [Abstract][Full Text] [Related]